Elevated expression of CDK4 in lung cancer

BackgroundThe aim of the present study was to analyze the expression of Cyclin-dependent kinase 4 (CDK4) in lung cancer and its correlation with clinicopathologic features. Furthermore, the involvement of CDK4-mediated cell cycle progression and its molecular basis were investigated in the pathogenesis of lung cancer.MethodsUsing immunohistochemistry analysis, we analyzed CDK4 protein expression in 89 clinicopathologically characterized lung cancer patients (59 males and 30 females) with ages ranging from 36 to 78 years and compared them to 23 normal lung tissues. Cases with cytoplasmic and nuclear CDK4 immunostaining score values greater than or equal to 7 were regarded as high expression while scores less than 7 were considered low expression. The correlation between the expression level of CDK4 and clinical features was analyzed. Furthermore, we used lentiviral-mediated shRNA to suppress the expression of CDK4 and investigate its function and molecular mechanism for mediating cell cycle progression.ResultsThe expression level of CDK4 protein was significantly increased in lung cancer tissues compared to normal tissues (P < 0.001). In addition, high levels of CDK4 protein were positively correlated with the status of pathology classification (P = 0.047), lymph node metastasis (P = 0.007), and clinical stage (P = 0.004) of lung cancer patients. Patients with higher CDK4 expression had a markedly shorter overall survival time than patients with low CDK4 expression. Multivariate analysis suggested the level of CDK4 expression was an independent prognostic indicator (P < 0.001) for the survival of patients with lung cancer. Use of lentiviral-mediated shRNA to inhibit the expression of CDK4 in lung cancer cell line A549 not only inhibited cell cycle progression, but also dramatically suppressed cell proliferation, colony formation, and migration. Furthermore, suppressing CDK4 expression also significantly elevated the expression of cell cycle regulator p21ConclusionOverexpressed CDK4 is a potential unfavorable prognostic factor and mediates cell cycle progression by regulating the expression of p21 in lung cancer

[1]  S. Poomsawat,et al.  Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[2]  M. Beckmann,et al.  Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. , 1999, The American journal of pathology.

[3]  R. Kratzke,et al.  Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. , 2008, Anticancer research.

[4]  G. Schneider,et al.  Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL‐induced apoptosis via downregulation of survivin , 2007, International journal of cancer.

[5]  M. Ghazizadeh,et al.  Role of cdk4, p16INK4, and Rb Expression in the Prognosis of Bronchioloalveolar Carcinomas , 2005, Respiration.

[6]  C. Conti,et al.  Enhanced malignant tumorigenesis in Cdk4 transgenic mice , 2004, Oncogene.

[7]  J. Slingerland,et al.  Phosphorylation of p27Kip1 Regulates Assembly and Activation of Cyclin D1-Cdk4 , 2008, Molecular and Cellular Biology.

[8]  M. Fukayama,et al.  Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma , 2004, International journal of cancer.

[9]  T. Shibata,et al.  Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics , 2010, Modern Pathology.

[10]  Zhen Liu,et al.  Decreased expression of updated NESG1 in nasopharyngeal carcinoma: Its potential role and preliminarily functional mechanism , 2011, International journal of cancer.

[11]  C. Conti,et al.  Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. , 2002, The American journal of pathology.

[12]  S. Knuutila,et al.  CDK4 is a probable target gene in a novel amplicon at 12q13.3–q14.1 in lung cancer , 2005, Genes, chromosomes & cancer.

[13]  Houwen Li State of the art:lung cancer in China. , 2003, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[14]  Yingdong Zhao,et al.  Journal of Translational Medicine Transcriptional Patterns, Biomarkers and Pathways Characterizing Nasopharyngeal Carcinoma of Southern China , 2008 .

[15]  M. Tachibana,et al.  Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  G. Åkerström,et al.  Cyclin-Dependent Kinase 4 (CDK4) Expression in Pancreatic Endocrine Tumors , 2007, Neuroendocrinology.

[17]  E. Knudsen,et al.  Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly , 2008, Oncogene.

[18]  G. Jianhua,et al.  A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. , 1998, Cancer letters.

[19]  M. Mi,et al.  BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. , 2008, International journal of oncology.

[20]  Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. , 2010, Cancer research.